Evidence map›Paper›PMID 30159654›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2019

Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy.

Mansi Shah, Meixiang Xu, Poonam Shah, Xiaoming Wang, Shannon M Clark, Maged Costantine, Holly A West, Tatiana N Nanovskaya, Mahmoud S Ahmed, Sherif Z Abdel-Rahman and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mansi ShahDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Meixiang XuDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Poonam ShahDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Xiaoming WangDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Shannon M ClarkDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Maged CostantineDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Holly A WestDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Tatiana N NanovskayaDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Mahmoud S AhmedDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Sherif Z Abdel-RahmanDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Raman VenkataramananMagee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Steve N CaritisMagee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Gary D V HankinsDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Erik RyttingDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, 77555, USA. erik.rytting@utmb.edu.
The University of Texas Medical Branch at Galveston · USUniversity of Pittsburgh · US

Funding

Pharmacokinetic and pharmacogenomic approach to indomethacin therapy in pregnancyR01HD083003 · NICHD · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RYTTING, ERIK · 2015 to 2018
$1.5M
Eunice Kennedy Shriver National Institute of Child Health and Human Development R01HD083003Eunice Kennedy Shriver National Institute of Child Health and Human Development U10HD04789108NICHD NIH HHS R01 HD083003
6 · The paper itself

Abstract

BACKGROUND AND

objectiveCytochrome P450 (CYP) 2C9 catalyzes the biotransformation of indomethacin to its inactive metabolite O-desmethylindomethacin (DMI). The aim of this work was to determine the effect of CYP2C9 polymorphisms on indomethacin metabolism in pregnant women.

methodsPlasma concentrations of indomethacin and DMI at steady state were analyzed with a validated LC-MS/MS method. DNA was isolated from subject blood and buccal smear samples. Subjects were grouped by genotype for comparisons of pharmacokinetic parameters.

resultsFor subjects with the *1/*2 genotype, the mean steady-state apparent oral clearance (CL/F

conclusionAlthough our results are limited by sample size and are not statistically significant, these data suggest that certain genetic polymorphisms of CYP2C9 may lead to an increased metabolic ratio and an increase in the clearance of indomethacin. More data are needed to assess the impact of CYP2C9 genotype on the effectiveness of indomethacin as a tocolytic agent.

Indexed as

AdolescentAdultAnti-Inflammatory Agents, Non-SteroidalCytochrome P-450 CYP2C9FemaleHumansIndomethacinPolymorphism, GeneticPregnancyYoung AdultAnti-Inflammatory Agents, Non-SteroidalCYP2C9 protein, humanCytochrome P-450 CYP2C9Indomethacin

Identifiers

PMID30159654
PMCPMC6380929
OpenAlexW2889485561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.